Literature DB >> 11243469

Integrin expression and usage by prostate cancer cell lines on laminin substrata.

M Edlund1, T Miyamoto, R A Sikes, R Ogle, G W Laurie, M C Farach-Carson, C A Otey, H E Zhau, L W Chung.   

Abstract

During prostate cancer progression, invasive glandular epithelial cells move out of the ductal-acinar architecture and through the surrounding basement membrane. Extracellular matrix proteins and associated soluble factors in the basal lamina and underlying stroma are known to be important regulators of prostate cell behaviors in both normal and malignant tissues. In this study, we assessed cell interactions with extracellular matrix and stromal factors during disease progression by characterizing integrin usage and expression in a series of parental and lineage-derived LNCaP human prostate cancer cell lines. Although few shifts in integrin expression were found to accompany disease progression, integrin heterodimer usage did change significantly. The more metastatic sublines were distinct in their use of alphavbeta3 and, when compared with parental LNCaP cells, showed a shift in alpha6 heterodimerization, a subunit critical not only for interaction with prostate basal lamina but also for interaction with the bone matrix, a favored site of prostate cancer metastases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243469

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  21 in total

1.  A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.

Authors:  Franklin M Chu; Joel Picus; Paula M Fracasso; Robert Dreicer; Zhihui Lang; Brenda Foster
Journal:  Invest New Drugs       Date:  2010-02-11       Impact factor: 3.850

2.  αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.

Authors:  Anindita Dutta; Jing Li; Carmine Fedele; Aejaz Sayeed; Amrita Singh; Shelia M Violette; Thomas D Manes; Lucia R Languino
Journal:  Biochem J       Date:  2015-03-15       Impact factor: 3.857

Review 3.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Authors:  Jochen G Schneider; Sarah R Amend; Katherine N Weilbaecher
Journal:  Bone       Date:  2010-09-17       Impact factor: 4.398

4.  Expression order of alpha-v and beta-3 integrin subunits in the N-methyl-N-nitrosourea-induced rat mammary tumor model.

Authors:  Robabeh Rezaeipoor; Eric J Chaney; Amy L Oldenburg; Stephen A Boppart
Journal:  Cancer Invest       Date:  2009-06       Impact factor: 2.176

5.  Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.

Authors:  Xueping Zhang; Marcia V Fournier; Joy L Ware; Mina J Bissell; Adly Yacoub; Zendra E Zehner
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

Review 6.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 7.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03

8.  Molecular pathway for cancer metastasis to bone.

Authors:  Sarmishtha De; Juhua Chen; Natalya V Narizhneva; Warren Heston; Jennifer Brainard; E Helene Sage; Tatiana V Byzova
Journal:  J Biol Chem       Date:  2003-07-28       Impact factor: 5.157

9.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Authors:  Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.

Authors:  J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-01-12       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.